Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Phone415-910-5717
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16
Next Earnings DateN/A
OptionableNot Optionable
Cortexyme (NASDAQ:CRTX) Frequently Asked Questions
What is Cortexyme's stock symbol?
Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."
What price target have analysts set for CRTX?
3 brokerages have issued twelve-month target prices for Cortexyme's stock. Their predictions range from $14.00 to $53.00. On average, they expect Cortexyme's stock price to reach $34.25 in the next year. This suggests a possible upside of 48.5% from the stock's current price. View Analyst Price Targets for Cortexyme.
What is the consensus analysts' recommendation for Cortexyme?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.
Has Cortexyme been receiving favorable news coverage?
Media headlines about CRTX stock have trended negative on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cortexyme earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Cortexyme.
Are investors shorting Cortexyme?
Cortexyme saw a increase in short interest in September. As of September 15th, there was short interest totalling 520,300 shares, an increase of 5.5% from the August 15th total of 493,200 shares. Based on an average daily volume of 64,800 shares, the short-interest ratio is currently 8.0 days. Currently, 5.8% of the company's shares are sold short. View Cortexyme's Current Options Chain.
Who are some of Cortexyme's key competitors?
Some companies that are related to Cortexyme include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of Cortexyme own?
Who are Cortexyme's key executives?
Cortexyme's management team includes the folowing people:
- Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
- Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
- Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
- Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
- Dr. Michael J. Detke, Chief Medical Officer (Age 52)
When did Cortexyme IPO?
(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.
When does the company's lock-up period expire?
Cortexyme's lock-up period expires on Tuesday, November 5th. Cortexyme had issued 4,412,000 shares in its public offering on May 9th. The total size of the offering was $75,004,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
How do I buy shares of Cortexyme?
Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cortexyme's stock price today?
One share of CRTX stock can currently be purchased for approximately $23.07.
How big of a company is Cortexyme?
What is Cortexyme's official website?
How can I contact Cortexyme?
Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]
MarketBeat Community Rating for Cortexyme (NASDAQ CRTX)
MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
